Market Closed -
Nasdaq
01:30:00 02/05/2024 am IST
5-day change
1st Jan Change
4.68
USD
+25.13%
+10.38%
+89.47%
Sales 2024 *
-
Sales 2025 *
-
Capitalization
330M
27.52B
Net income 2024 *
-168M
-14.02B
Net income 2025 *
-193M
-16.1B
EV / Sales 2024 *
-
Net cash position
2024
*
208M
17.32B
Net cash position
2025
*
339M
28.27B
EV / Sales 2025 *
-
P/E ratio 2024 *
-1.67
x
P/E ratio 2025 *
-1.68
x
Employees
80
Yield 2024 *
-
Yield 2025 *
-
Free-Float
96.79%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Ventyx Biosciences, Inc. Announces Resignation of Christopher Krueger as Chief Business Officer, Effective on April 15, 2024
06/04
CI
Transcript : Ventyx Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM
14/03
Canaccord Genuity Trims Price Target on Ventyx Biosciences to $15 From $16, Maintains Buy Rating
13/03
MT
North American Morning Briefing : Stock Futures -2-
13/03
DJ
Ventyx Biosciences Shares Rise After Oppenheimer, Wells Fargo Upgrades
13/03
MT
Oppenheimer Upgrades Ventyx Biosciences to Outperform From Perform, $12 Price Target
12/03
MT
Wells Fargo Upgrades Ventyx Biosciences to Overweight From Equal Weight, Raises Price Target to $16 From $7
12/03
MT
Canaccord Genuity Adjusts Ventyx Biosciences' Price Target to $16 From $20, Maintains Buy Rating
11/03
MT
Transcript : Ventyx Biosciences, Inc. - Special Call
11/03
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
11/03
CI
Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in funding
06/03
CI
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target
29/02
MT
Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
28/02
CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
28/02
CI
Wells Fargo Cuts Ventyx Biosciences Price Target to $3 From $8, Maintains Equal Weight Rating
19/12
MT
More news
VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
30/04
PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
30/04
BU
VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
29/04
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX
28/04
PR
The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
26/04
PR
More press releases
1 day +25.13%
1 week +10.38%
Current month +25.13%
1 month -16.28%
3 months +108.93%
6 months -67.59%
Current year +89.47%
More quotes
Managers
Title Age Since
Founder
68
01/18/01
Director of Finance/CFO
49
01/21/01
Chief Tech/Sci/R&D Officer
65
01/19/01
Members of the board
Title Age Since
Director/Board Member
69
01/18/01
Director/Board Member
61
11/23/11
Chairman
53
01/21/01
More insiders
Date
Price
Change
Volume
01/24/01
4.68
+25.13%
2,275,846
30/24/30
3.74
-2.48%
2,856,835
29/24/29
3.835
-2.42%
947,340
26/24/26
3.93
-3.20%
529,730
25/24/25
4.06
-4.25%
586,706
Delayed Quote
Nasdaq, May 02, 2024 at 01:30 am IST
More quotes
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Companyâs pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
More about the company
Last Close Price
4.68
USD
Average target price
10.8
USD
Spread / Average Target
+130.77%
Consensus
1st Jan change
Capi.
+89.47% 330M -1.17% 104B +2.87% 97.47B +2.13% 22.25B -14.77% 21.68B -8.79% 18.2B -39.98% 17.02B -13.21% 16.36B +8.55% 14.39B +35.75% 12.37B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1